L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 15:16:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     50 TO ITERATE

100.0% PROCESSED      50 ITERATIONS                          41 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          576 TO     1424
PROJECTED ANSWERS:             436 TO     1204

L2            41 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:16:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1036 TO ITERATE

100.0% PROCESSED    1036 ITERATIONS                         871 ANSWERS
SEARCH TIME: 00.00.01

L3           871 SEA SSS FUL L1
```

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   145.42     145.63

FILE 'CAPLUS' ENTERED AT 15:18:33 ON 05 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 5 Sep 2002  VOL 137 ISS 10
FILE LAST UPDATED: 4 Sep 2002  (20020904/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.

=> s l3
L5         680 L3

=> s l3 and syrup
           680 L3
         10002 SYRUP
          6440 SYRUPS
         12457 SYRUP
                (SYRUP OR SYRUPS)
L6          18 L3 AND SYRUP

=> d l6 1-18 ibib abs hitstr

L6   ANSWER 1 OF 18  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:         2002:412339  CAPLUS
DOCUMENT NUMBER:          136:374811
TITLE:                    Antihistamine composition
PATENT ASSIGNEE(S):       Otkrytoe Aktsionernoe Obshchestvo "Khimiko-
                          Farmatsevticheskii Kombinat "Akrikhin", Russia
SOURCE:                   Russ., No pp. given
                          CODEN: RUXXE7
DOCUMENT TYPE:            Patent
LANGUAGE:                 Russian
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     RU 2165255         C1   20010420      RU 2000-118551   20000714
AB   A compn. suitable for treatment of seasonal and all-year-round allergic
```

rhinitis, conjunctivitis, grass pollen allergy, urticaria, and other allergic conditions is made in the form of **syrup** and contains, g/100 mL, loratadine 0.001-5.0, saccharide 10.0-70.0, alc. 0.5-45.0, and pharmaceutically acceptable acid adjusting pH to 2-4 (preferably 2.5-3.5) to 100 mL. The compn. can also contain an odorant and colorant. The product exhibits prolonged storage time (at least two years) and improved organoleptic characteristics.

IT **79794-75-5**, Loratidine
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(antihistamine compn. contg. loratadine)

RN 79794-75-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	2002:408516 CAPLUS
DOCUMENT NUMBER:	136:406871
TITLE:	As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation
INVENTOR(S):	Tam, Peter; Gesundheit, Neil; Wilson, Leland F.
PATENT ASSIGNEE(S):	Vivus, Inc., USA
SOURCE:	PCT Int. Appl., 40 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002041883	A2	20020530	WO 2001-US44065	20011121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-721412 A 20001121

AB A method is provided for treatment of premature ejaculation by administration of an antidepressant drug selected from tricyclic antidepressants, tetracyclic antidepressants, MAO inhibitors, azaspirone antidepressants, and atypical non-SRI antidepressants. In a preferred embodiment, administration is on as "as-needed" basis, i.e., the drug is administered immediately or at most several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided. An effervescent tablet contained clomipramine hydrochloride 300, sodium bicarbonate 1985, and citric acid 1000 mg. Efficacy of the compns. were tested in volunteers.

IT **3964-81-6**, Azatadine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation)

RN 3964-81-6 CAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)- (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:385008 CAPLUS
DOCUMENT NUMBER: 136:390999
TITLE: Oral compositions containing coolants and sweeteners having improved consumer aesthetics
INVENTOR(S): Lee, Kuo-Chung Mark
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6391886	B1	20020521	US 2000-729406	20001204
WO 2002045714	A1	20020613	WO 2001-US45035	20011130

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-729406 A 20001204

AB Oral compns. contg. therapeutic agents wherein the undesirable consumer aesthetics assocd. with these agents are mitigated using coolants and sweeteners. Thus, a cough treatment compn. contained dextromethorphan 2.20. propylene glycol 42.45, Pluronic-F127 29.71, water 12.08, EtOH 10.91, sodium metabisulfite 0.10, disodium EDTA 0.10, Eucalyptus flavor 0.45, menthol 0.20 WS-3 0.15, 1-menthone-/D-isomenthone glycerin ketal (MGA) 0.30, 3-l-menthoxypropane-1,2-diol 0.10, sodium saccharin 0.60, potassium acesulfame 0.50, and monoammonium glycyrrhizinate 0.15%.

IT **79794-75-5**, Loratidine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. contg. coolants and sweeteners having improved consumer aesthetics)

RN 79794-75-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:115043 CAPLUS

DOCUMENT NUMBER: 136:252614

TITLE: Quantitation of antihistamines in pharmaceutical preparations by liquid chromatography with a micellar mobile phase of sodium dodecyl sulfate and pentanol

AUTHOR(S): Gil-Agusti, Mayte; Monferrer-Pons, Llorenc; Esteve-Romero, Josep; Garcia-Alvarez-Coque, Maria Celia

CORPORATE SOURCE: Universitat Jaume I, Area de Quimica Analitica, Castello, 12080, Spain

SOURCE: Journal of AOAC International (2001), 84(6), 1687-1694
CODEN: JAINEE; ISSN: 1060-3271

PUBLISHER: AOAC International

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A reversed-phase liq. chromatog. procedure with a micellar mobile phase of sodium dodecyl sulfate (SDS), contg. a small amt. of pentanol, was developed for the control of 7 antihistamines of diverse action in pharmaceutical prepns. (tablets, capsules, powders, solns., and **syrups**): azatadine, carbinoxamine, cyclizine, cyproheptadine, diphenhydramine, doxylamine, and tripelennamine. The retention times of the drugs were <9 min with a mobile phase of 0.15M SDS-6% (vol./vol.) pentanol. The recoveries with respect to the declared compns. were in the range of 93-110%, and the intra- and interday repeatabilities and interday

reproducibility were <1.2%. The results were similar to those obtained with a conventional 60 + 40 (vol./vol.) methanol-water mixt., with the advantage of reduced toxicity, flammability, environmental impact, and cost of the micellar-pentanol solns. The lower risk of evapn. of the org. solvent dissolved in the micellar solns. also increased the stability of the mobile phase.

IT **3964-81-6**, Azatadine
RL: ANT (Analyte); ANST (Analytical study)
(quantitation of antihistamines in pharmaceutical prepns. by liq. chromatog. with a micellar mobile phase of sodium dodecyl sulfate and pentanol)

RN 3964-81-6 CAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:472476 CAPLUS
DOCUMENT NUMBER: 135:56066
TITLE: Treating allergic and inflammatory conditions
INVENTOR(S): Affrime, Melton F.; Banfield, Christopher R.; Gupta, Samir K.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045688	A2	20010628	WO 2000-US34418	20001219
WO 2001045688	A3	20020502		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-172911P P 19991221

AB The use of desloratadine for the prepn. of a medicament for treating and/or preventing an allergic and inflammatory condition of the skin or

upper and lower airway passages in a pediatric patient and a pediatric pharmaceutical compn. effective for such treating and/or preventing which comprises an effective amt. of desloratadine and a pharmaceutically acceptable carrier are disclosed. Examples are given of the pharmacokinetics of desloratadine in pediatric volunteers following administration of a **syrup** formulation. The data was used to establish effective dosage regimens.

IT **100643-71-8**, Desloratadine
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(desloratadine pediatric **syrup** for treating allergic and inflammatory conditions)

RN 100643-71-8 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:396644 CAPLUS
DOCUMENT NUMBER: 135:24671
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248363	B1	20010619	US 1999-447690	19991123
EP 1233756	A1	20020828	EP 2000-980761	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 1999-447690 A 19991123
WO 2000-US32255 W 20001122

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical compn. includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical compn. includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A compn. contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

IT **79794-75-5**, Loratadine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

RN 79794-75-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:228695 CAPLUS
DOCUMENT NUMBER: 134:247244
TITLE: Desloratadine for treating allergic and inflammatory conditions
INVENTOR(S): Affrime, Melton B.; Banfield, Christopher R.; Gupta, Samir K.; Padhi, Desmond
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021161	A2	20010329	WO 2000-US25595	20000919
WO 2001021161	A3	20020117		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1214072 A2 20020619 EP 2000-966746 20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.: US 1999-400147 A 19990921
WO 2000-US25595 W 20000919

AB The use of desloratadine is disclosed for the prepn. of a medicament for treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages in a human while avoiding the food effect assocd. with non-sedating antihistamines, e.g., loratadine or fexofenadine.

IT **100643-71-8**, Desloratadine
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(desloratadine for treatment of allergic and inflammatory conditions)

RN 100643-71-8 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



IT **100643-71-8D**, Desloratadine, derivs.
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(desloratadine for treatment of allergic and inflammatory conditions)

RN 100643-71-8 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



L6 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:736162 CAPLUS
DOCUMENT NUMBER: 133:301192
TITLE: Stabilized antihistamine **syrup** containing loratadine
INVENTOR(S): Munayyer, Farah J.; Guazzo, Frank; Stupak, Elliot I.; Chaudry, Imtiaz A.; Sequeira, Joel A.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6132758	A	20001017	US 1998-88128	19980601
WO 9962516	A1	19991209	WO 1999-US10469	19990527
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9943085	A1	19991220	AU 1999-43085	19990527
EP 1082117	A1	20010314	EP 1999-955215	19990527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
JP 2002516860	T2	20020611	JP 2000-551772	19990527
NL 1012191	A1	19991203	NL 1999-1012191	19990531
NL 1012191	C2	20000104		
NO 2000006079	A	20001130	NO 2000-6079	20001130

PRIORITY APPLN. INFO.: US 1998-88128 P 19980601
WO 1999-US10469 W 19990527

AB An antihistaminic **syrup** is stabilized against degrdn. of the active ingredient, i.e. loratadine, descarboethoxyloratadine, and azatadine, by the addn. of .apprx. 0.05-5 mg/mL of an aminopolycarboxylic acid such as a salt of EDTA. The **syrup** further comprises a decongestant, an analgesic, an antitussive, an expectorant, or any combination of two or more.

IT **79794-75-5D**, Loratadine, hydroxymethyl derivs.
RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)
(stabilized antihistamine **syrup** contg. loratadine)
RN 79794-75-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



IT **3964-81-6**, Azatadine **79794-75-5**, Loratadine
100643-71-8, Descarboethoxyloratadine
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilized antihistamine **syrup** contg. loratadine)

RN 3964-81-6 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)- (9CI) (CA INDEX NAME)



RN 79794-75-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 100643-71-8 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:444853 CAPLUS
DOCUMENT NUMBER: 133:68315
TITLE: The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine **syrup** in children aged 2 to 5 years
AUTHOR(S): Salmun, Luis M.; Herron, Jerry M.; Banfield, Christopher; Padhi, Desmond; Lorber, Richard; Affrime, Melton B.
CORPORATE SOURCE: Allergy/Respiratory Diseases Clinical Research, Schering-Plough Research Institute, Kenilworth, NJ, USA
SOURCE: Clinical Therapeutics (2000), 22(5), 613-621
CODEN: CLTHDG; ISSN: 0149-2918
PUBLISHER: Excerpta Medica, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Objective: We assessed the pharmacokinetics and tolerability of 5 mg loratadine **syrup** (1 mg/mL) in children aged 2 to 5 yr. Methods: Two studies were undertaken. A single-dose, open-label bioavailability study was performed to characterize the pharmacokinetic profiles of loratadine and its metabolite desloratadine. Plasma concns. of loratadine and desloratadine were detd. at 0, 1, 2, 4, 8, 12, 24, 48, and 72 h after a single administration of 5 mg loratadine **syrup** to 18 healthy children (11 male, 7 female; 12 black, 5 white, 1 other; mean age .+-. SD, 3.8.+-.1.1 yr; mean wt. .+-. SD, 17.4.+-.4.4 kg). In addn., a randomized, double-blind, placebo-controlled, parallel-group study was performed to assess the tolerability of 5 mg loratadine **syrup** after multiple doses. Loratadine (n = 60) or placebo (n = 61) was given once daily for 15 days to children with a history of allergic rhinitis or chronic idiopathic urticaria. In the loratadine group, 27 boys and 33 girls (52 white, 8 black) were enrolled, with a mean age .+-. SD of 3.67.+-.1.13 yr and a mean wt. .+-. SD of 17.2.+-.3.8 kg. In the placebo group, 27 boys and 34 girls (53 white, 7 black, 1 Asian) were enrolled, with a mean age .+-. SD of 3.52.+-.1.12 yr and a mean wt. .+-. SD of 17.3.+-.2.9 kg. Tolerability was assessed based on electrocardiog. results, occurrence of adverse events, changes in vital signs, and results of lab. tests and phys. examns. Results: The peak plasma concns. of loratadine and desloratadine were 7.78 and 5.09 ng/mL, resp., obsd. 1.17 and 2.33 h after administration of loratadine; the areas under the plasma concn.-time curve to the last quantifiable time point for loratadine and desloratadine were 16.7 and 87.2 ng.cntdot.h/mL, resp. Single and multiple doses were well tolerated, with no adverse events occurring with greater frequency after multiple doses of loratadine than after placebo. Electrocardiog. parameters were not altered by loratadine compared with placebo. There

were no clin. meaningful changes in other tolerability assessments. Conclusion: Loratadine was well tolerated in this small, selected group of children aged 2 to 5 yr at a dose providing exposure similar to that with the adult dose (ie, 10 mg once daily).

IT **79794-75-5**, Loratadine
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmacokinetics, electrocardiog. effects, and tolerability of loratadine **syrup** in children aged 2 to 5 yr)

RN 79794-75-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



IT **100643-71-8**, Desloratadine
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pharmacokinetics, electrocardiog. effects, and tolerability of loratadine **syrup** in children aged 2 to 5 yr)

RN 100643-71-8 CAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:783935 CAPLUS

DOCUMENT NUMBER: 132:15660

TITLE: A stabilized antihistamine **syrup** containing aminopolycarboxylic acid as stabilizer

INVENTOR(S): Munayyer, Farah J.; Guazzo, Frank; Stupak, Elliot I.;

Chaudry, Imtiaz A.; Sequeira, Joel A.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962516	A1	19991209	WO 1999-US10469	19990527
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6132758	A	20001017	US 1998-88128	19980601
AU 9943085	A1	19991220	AU 1999-43085	19990527
EP 1082117	A1	20010314	EP 1999-955215	19990527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
JP 2002516860	T2	20020611	JP 2000-551772	19990527
NO 2000006079	A	20001130	NO 2000-6079	20001130

PRIORITY APPLN. INFO.: US 1998-88128 P 19980601
WO 1999-US10469 W 19990527

AB An antihistaminic **syrup** is stabilized against degrdn. of the active ingredient (e.g., loratadine), by the addn. of and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid such as a salt of EDTA. Thus, a **syrup** contained micronized loratadine 1, citric acid 8.78, flavoring agent 2.5, glycerin 100, propylene glycol 100, sodium benzoate 1, disodium EDTA 0.25, and sucrose 600 mg and water to 1.0 mL. In a storage stability study, the results showed a significant inhibition by EDTA of the degrdn. of loratadine during the severe storage conditions of the test.

IT **3964-81-6**, Azatadine **79794-75-5**, Loratadine
100643-71-8, DescarboethoxyLoratadine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilized antihistamine **syrup** contg. aminopolycarboxylic acid as stabilizer)

RN 3964-81-6 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)- (9CI) (CA INDEX NAME)



RN 79794-75-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 100643-71-8 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:738618 CAPLUS
DOCUMENT NUMBER: 132:69417
TITLE: Densitometric determination of loratadine in pharmaceutical preparations, and validation of the method
AUTHOR(S): Indrayanto, Gunawan; Darmawan, Lindawati; Widjaja, Sonja; Noorrizka, Gusti
CORPORATE SOURCE: Laboratory of Pharmaceutical Biotechnology, Faculty of Pharmacy, Airlangga University, Surabaya, 60286, Indonesia
SOURCE: Journal of Planar Chromatography--Modern TLC (1999), 12(4), 261-264
CODEN: JPCTE5; ISSN: 0933-4173
PUBLISHER: Research Institute for Medicinal Plants
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A simple and rapid densitometric method was developed for detn. of loratadine in pharmaceuticals. After diln. of **syrups**, or extn. of the analyte from tablets with 96% ethanol, samples were spotted on precoated silica gel plates which were then developed with CHCl3-EtOAc-acetone (5:7:7). Quant. evaluation was performed by measuring

the absorbance reflectance of the analyte spots at .lambda. 250 nm. The densitometric method is selective, precise, and accurate and can be used for routine anal. of **syrup** and tablet prepns. in pharmaceutical industry quality-control labs.

IT **79794-75-5**, Loratadine
RL: ANT (Analyte); ANST (Analytical study)
(densitometric detn. of loratadine in pharmaceuticals)

RN 79794-75-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:58864 CAPLUS
DOCUMENT NUMBER: 130:100701
TITLE: Soluble, gum-containing, coated chewable tablet
INVENTOR(S): Gergely, Gerhard; Gergely, Irmgard; Gergely, Thomas
PATENT ASSIGNEE(S): Austria
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 890358	A1	19990113	EP 1997-111783	19970710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 9902137	A1	19990121	WO 1998-EP3306	19980603
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 1997-111783 19970710

AB Coated chewable pharmaceutical tablets are provided which dissolve and release their active ingredients over a period of several minutes, leaving no residue. These tablets are prepd. by mixing powd. chewable components

(e.g. polysaccharide gums, dried sugar **syrups**, sol. cellulose derivs.) with liq. **syrups** (e.g. sugar, sugar alc., or gelatin **syrups**) and fatty or waxy components (e.g. beeswax, triglyceride fats, solid paraffin, ozocerite) to form a crumbly mass which is cooled to <0.degree., ground, compressed into tablets at <10.degree., and coated. The tablets have a moisture content of .apprx.4-7%; the moisture is immobilized by cooling, becomes mobile on heating during compression, and provides the required softness on contacting the water-sol. ingredients by converting them to a highly viscous, thixotropic, chewable mass. Thus, tablets were prepd. contg. spray-dried gum arabic 16.50, glycerin 0.30, rice starch 7.80, dried glucose **syrup** 25.00, beeswax 0.95, hydrogenated coconut oil 5.60, liq. glucose **syrup** 35.95, aspartame 0.30, Maltrin M700 7.475, and salbutamol sulfate 0.125%.

IT **79794-75-5**, Loratadine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gum-contg., coated chewable tablet)

RN 79794-75-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:364739 CAPLUS
DOCUMENT NUMBER: 129:45288
TITLE: Pharmaceutical suspension systems
INVENTOR(S): Singh, Kiran Pal; Popli, Shankar D.
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5759579	A	19980602	US 1996-702777	19961205
WO 9824414	A1	19980611	WO 1997-US21935	19971202

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9876224	A1	19980629	AU 1998-76224	19971202
EP 944383	A1	19990929	EP 1997-949698	19971202

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI

PRIORITY APPLN. INFO.: US 1996-702777 19961205
WO 1997-US21935 19971202

AB A pharmaceutically acceptable liq. suspension system is provided for finely divided solid pharmaceutical actives incompletely sol. in water. The suspension system comprises water, xanthan gum and hydroxypropyl Me cellulose. Among the benefits provided by the invention is the capability of the excipient suspending base to be admixed with the solid pharmaceuticals without causing flocculation or foaming esp. in batches greater than 10 L. A suspension contained acetaminophen 3.2, brompheniramine maleate 0.02, pseudoephedrine.cntdot.HCl 0.3, Methocel K4M 0.35, xanthan gum 0.5, sucrose 10, Polysorbate 80 0.1, corn syrup 40, sorbitol soln. 10, glycerol 10, propylene glycol 2, methylparaben 0.16, propylparaben 0.04, disodium EDTA 0.05, maltol 0.0075, D&C Red #33 0.0015, FD&C Blue #1 0.00032, flavors 0.86, and purified water to 100 %.

IT **3964-81-6**, Azatadine.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suspension systems contg. xanthan gum and hydroxypropyl Me cellulose for solid pharmaceuticals incompletely sol. in water)

RN 3964-81-6 CAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)- (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	1997:233175 CAPLUS
DOCUMENT NUMBER:	126:229736
TITLE:	Spectrofluorimetric determination of some antihistaminic drugs
AUTHOR(S):	El-Khateeb, S.Z.; Elragehy, N.A.; Badawey, A.M.
CORPORATE SOURCE:	Analytical Chemistry Department, Faculty of Pharmacy, Cairo, University, Cairo, 11562, Egypt
SOURCE:	Bulletin of the Faculty of Pharmacy (Cairo University) (1995), 33(2), 7-12 CODEN: BFPHA8; ISSN: 1110-0931
PUBLISHER:	Cairo University, Faculty of Pharmacy
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB A simple, sensitive and accurate spectrofluorimetric procedure for the quant. detn. of some antihistaminic agents has been introduced. The method was based on measuring the native fluorescence of each compd. in a

suitable solvent. The investigated drugs were mequitazine (Mz), terfenadine (Td) and loratadine (Ld). The ethanolic - sulfuric acid soln. of (Mz) exhibited max. excitation and emission at .lambda. 300 nm, and .lambda. 385 nm, resp. (Td) showed max. excitation at .lambda. 265 nm and max. emission at .lambda. 293 nm in the same solvent. For (Ld) the excitation and emission spectra were obtained in 0.1N sulfuric acid soln. revealing max. excitation and emission at .lambda. 303 nm and .lambda. 455 nm, resp. Linearity was obtained upon detn. of authentic samples of (Mz) (Td) and (Ld) in the concn. ranges 0.1-3.5 .mu.g.ml-1, 0.2-11.0 .mu.g.ml-1, and 0.2-8.0 .mu.g.ml-1,, resp. Reproducibility was checked, where the mean percentage recoveries were found to be 100.41 .+-. 0.377, 100.03 .+-. 0.675 and 100.01 .+-. 0.628, for (Mz), (Td), & (Ld) resp. The proposed procedure was successfully applied for detn. of (Ld) and (Td) in their tablet form, and (Mz) was detd. in both its tablets and **syrup**. The validity of the suggested procedure was assessed by applying the std. addn. technique. Moreover, results of the suggested procedure have been statistically compared to those of ref. methods, revealing high accuracy and good precision.

IT **79794-75-5**, Loratadine
RL: ANT (Analyte); ANST (Analytical study)
(detn. of antihistaminic drugs by spectrofluorimetry)

RN 79794-75-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:584139 CAPLUS
DOCUMENT NUMBER: 125:204579
TITLE: Taste masking liquids based on polyethylene glycol and cellulosic material
INVENTOR(S): Popli, Shankar Dass; Go, Zenaida Ong
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9623486	A1	19960808	WO 1996-US577	19960116

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT,

LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE

US 5616621	A	19970401	US 1995-380540		19950130
CA 2211677	AA	19960808	CA 1996-2211677		19960116
AU 9647576	A1	19960821	AU 1996-47576		19960116
AU 698718	B2	19981105			
EP 806939	A1	19971119	EP 1996-903512		19960116
EP 806939	B1	20020814			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE					
BR 9606863	A	19971223	BR 1996-6863		19960116
CN 1179098	A	19980415	CN 1996-192677		19960116
FI 9703147	A	19970929	FI 1997-3147		19970729
NO 9703480	A	19970929	NO 1997-3480		19970729
PRIORITY APPLN. INFO.:			US 1995-380540	A	19950130
			WO 1996-US577	W	19960116

AB A pharmaceutically acceptable taste masking liq. excipient base for administration of relatively large amts. of unpleasantly tasting medicines is provided, said excipient base having higher than normal viscosities (150-1000 cP at 50 rpm and 150-1200 cP at 10 rpm) due to a combination of polyethylene glycol and cellulosic material in the ratio of 100:1-20:1, resp. A formulation having an acceptable flavor and taste was prepd. contg. acetaminophen 20 g, polyethylene glycol 1450 50 g, propylene glycol 75 mL, glycerin 25 mL, corn **syrup** 225 mL, sorbitol soln. 25 mL, menthol 0.12 g, citric acid 3 g, Na benzoate 0.75 g, saccharin Na 2.8 g, coloring and sweetener 0.55 g, Na CM-cellulose 0.5 g, and water up to 500 mL.

IT **3964-81-6**, Azatadine
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(taste masking liqs. based on polyethylene glycol and cellulosic material)

RN 3964-81-6 CAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)- (9CI) (CA INDEX NAME)



L6 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	1995:899177 CAPLUS
DOCUMENT NUMBER:	123:296637
TITLE:	Mucoadhesive polymers as vehicles for oral compositions
INVENTOR(S):	Singh, Nikhilesh Nihala; Carella, Anne Marie; Smith, Ronald Lee
PATENT ASSIGNEE(S):	Procter and Gamble Co., USA
SOURCE:	PCT Int. Appl., 26 pp. CODEN: PIXXD2

09/744,603

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9523591	A1	19950908	WO 1995-US2207	19950223
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5458879	A	19951017	US 1994-316172	19940930
AU 9519683	A1	19950918	AU 1995-19683	19950223
AU 702889	B2	19990311		
EP 748212	A1	19961218	EP 1995-912585	19950223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
BR 9506982	A	19970916	BR 1995-6982	19950223
JP 09510703	T2	19971028	JP 1995-522935	19950223
FI 9603421	A	19960902	FI 1996-3421	19960902
NO 9603673	A	19960903	NO 1996-3673	19960903

PRIORITY APPLN. INFO.: US 1994-205665 19940303
US 1994-316172 19940930
WO 1995-US2207 19950223

AB Disclosed are oral pharmaceutical vehicle compns. comprising 0.05-20% of a water-sol. mucoadhesive. The mucoadhesives coat and adhere to mucous membranes such as the throat, therefore the compn. is suitable for the treatment of irritation, pain, and discomfort assocd. with laryngopharyngitis and cold. An oral soln. contained acetaminophen 5.000, pseudoephedrine HCl 10.300, propylene glycol 15.000, polyethylene oxide 0.450, Na CMC 0.450, Na citrate 0.522, citric acid 0.338, **syrup** 40.000, colorants 0.008, flavor 0.500, 95% alc. 5.000, and purified water to 100.000 wt./vol.%.

IT **3964-81-6**, Azatadine **79794-75-5**, Loratadine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mucoadhesives for oral prepns. for treatment of cough and discomfort assocd. with laryngopharyngitis)

RN 3964-81-6 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)- (9CI) (CA INDEX NAME)



RN 79794-75-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:564007 CAPLUS
DOCUMENT NUMBER: 121:164007
TITLE: Pharmaceutical compositions containing 3-1-menthoxy propane 1,2-diol for treatment of cold symptoms
INVENTOR(S): Upson, James Grigg; Russell, Carmelita Macklin
PATENT ASSIGNEE(S): Procter and Gamble Co., USA
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9408551	A2	19940428	WO 1993-US8887	19930922
WO 9408551	A3	19940623		
W: AU, CA, FI, JP, KR, NO, NZ, RU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 662840	A1	19950719	EP 1993-921692	19930922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08502288	T2	19960312	JP 1993-510004	19930922
AU 678561	B2	19970605	AU 1993-49307	19930922
AU 9349307	A1	19940509		

PRIORITY APPLN. INFO.: US 1992-955013 19921009
WO 1993-US8887 19930922

AB Oral or nasal pharmaceutical compns. comprising 3-1-menthoxy propane 1,2-diol (I) are useful for treatment of cough, cold, cold-like, allergy and/or flu symptoms. A cough drop contained menthol 0.2211, eucalyptus oil 0.1455, I 0.0700, N-ethyl-p-menthane-3-carboxamide 0.0300, FD&C blue #1 0.0022, sugar and corn **syrup** q.s. 100%.

IT **3964-81-6**, Azatadine **79794-75-5**, Loratadine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral and nasal pharmaceuticals contg. menthoxypropanediol and, for treatment of cold symptoms)

RN 3964-81-6 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)- (9CI) (CA INDEX NAME)



RN 79794-75-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:498954 CAPLUS
DOCUMENT NUMBER: 121:98954
TITLE: Sensitive gas-liquid chromatographic method for the determination of loratadine and its major active metabolite, descarboethoxyloratadine, in human plasma using a nitrogen-phosphorus detector
AUTHOR(S): Johnson, Richard; Christensen, Jeffrey; Lin, Chin-Chung
CORPORATE SOURCE: Wisconsin Analytical and Research Services, Madison, WI, 53713, USA
SOURCE: Journal of Chromatography, B: Biomedical Sciences and Applications (1994), 657(1), 125-31
CODEN: JCBBEP; ISSN: 1387-2273
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A sensitive gas-liq. chromatog. (GLC) method was developed for the detn. of loratadine, a long-acting tricyclic antihistamine, and its active metabolite, descarboethoxyloratadine, in human plasma. The method involved extn. with org. solvent at neutral and alk. pH. The org. layer from the neutral pH extn. was evapd. to dryness, reconstituted and injected into the GLC system. On the other hand, to the org. layer from the alk. pH extn. trifluoroacetic anhydride was added. Following addn. of H2O, the mixt. was centrifuged and the org. layer was evapd. to dryness, reconstituted and injected onto the GLC system that was equipped with a nitrogen specific detector and a fused-silica capillary column. The linearity for both loratadine and descarboxyloratadine were demonstrated

with r .gtoreq.0.998 at concns. ranging from 0.1 to 30 ng/mL. The results showed that the GLC method was accurate (bias .ltoreq.12%) and precise (coeff. of variation, C.V., .ltoreq.12%) for loratadine and descarboethoxyloratadine. The limit of quantitation was 0.1 ng/mL for loratadine with a C.V. of 9.2% and for descarboethoxyloratadine with a C.V. of 5.3%. The GLC method described has been demonstrated to be useful for the detn. of loratadine and descarboethoxyloratadine in plasma samples of pediatric volunteers following oral administration of a single dose of 10 mg of loratadine **syrup**.

IT **79794-75-5**, Loratadine **100643-71-8**, Descarboethoxyloratadine
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, in human blood by gas-liq. chromatog. with nitrogen-phosphorus detection)

RN 79794-75-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 100643-71-8 CAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



=>